Medical treatment focused on Type 2 inflammation, such as IgE, Th2 cytokines, and group 2 innate lymphoid cells (ILC2s) due to TSLP, is probably insufficient to maintain good long-term management (complete remission) for severe asthma. This evidence concerns the gene IGHE and asthma.